Aspira Women's Health Inc.
03/25/2026 | Press release | Distributed by Public on 03/25/2026 14:42
Amendment to Current Report (Form 8-K/A)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 23, 2025
ASPIRA WOMEN'S HEALTH INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-34810 |
|
33-0595156 |
|
(State or other jurisdiction of |
|
(Commission |
|
(IRS Employer |
|
incorporation or organization) |
|
File Number) |
|
Identification No.) |
12117 Bee Caves Road, Building III, Suite 100
Austin, TX 78738
(Address of principal executive office) (Zip Code)
(512) 519-0400
(Registrants' telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.001 |
|
AWHL |
|
OTC QX Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
Explanatory Note
On December 23, 2025, Aspira Women's Health Inc. ("Aspira") disclosed that we had entered into a Laboratory Services Agreement (the "Agreement") with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories ("Mayo"), effective as of December 16, 2025.
The Agreement was not filed at the time of the 8-K filing as Aspira was still finalizing appropriate redactions of certain information that is private or confidential.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
|
|
|
|
|
Exhibit No. |
|
Description |
|
10.1 |
Laboratory Services Agreement, dated as of December 16, 2025 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: March 25, 2026
|
ASPIRA WOMEN'S HEALTH INC. |
||
|
By: |
/s/ Brian Hungerford |
|
|
Name: |
Brian Hungerford |
|
|
Title: |
Chief Financial Officer |
|
Aspira Women's Health Inc. published this content on March 25, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 25, 2026 at 20:42 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]